About QbD Growth BV

Primary Industry: Life Sciences

Founded by Bart Van Acker in 2011, QbD Growth BV (Quality by Design) is a leader in the life sciences and healthcare industry, helping companies develop and produce high-quality products. With expertise across regulatory affairs, clinical, quality assurance, software solutions, and go-to-market strategies, QbD supports companies in Pharma, Biotech, Medical Devices, and IVD sectors. QbD operates internationally, with over 600 consultants across Belgium, the Netherlands, Spain, France, the UK, Switzerland, Mexico, Colombia, and the United States.

“Very happy with the service delivered by Dragon Argent while they were supporting us with our most recent acquisition in the UK. Acquiring a new company in another country comes with its challenges but the help provided by Dragon Argent during our legal and financial due diligence was exactly what we needed. I recommend working with Dragon Argent and would decide to work with them again in the future if another M&A opportunity arises in the UK.”

Jurgen Verstraete | Founder, QbD Group

To enhance its regulatory affairs services and bolster its presence in the UK, QbD identified a promising acquisition target. The target company offered tailored consultancy services spanning product development, regulatory approvals, market launches, and lifecycle management.

Known for its strong connections with the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), this acquisition would position QbD to provide more specialized regulatory support across a variety of therapeutic areas and pharmaceutical forms.

QbD engaged Dragon Argent to manage the legal aspects of the transaction, ensuring a seamless and thorough M&A process. Dragon Argent’s team conducted both financial and legal due diligence, prepared critical transaction documents—including the share purchase agreement (SPA)—and addressed any potential concerns identified during due diligence. Their expertise extended to negotiating terms with the seller’s legal team and providing QbD with real-time updates to maintain transparency throughout the transaction.

The combined legal and financial due diligence provided QbD with a holistic view of the acquisition, allowing for integrated advice and mitigating risks effectively.

With the acquisition completed, QbD successfully expanded its regulatory affairs division, strengthening its ability to support pharmaceutical customers, including those advancing complex therapeutic products like ATMPs (Advanced Therapy Medicinal Products). This acquisition has not only expanded QbD’s regulatory expertise but also enhanced its capacity to serve UK-based clients with more comprehensive regulatory support.

Dragon Argent continues to support QbD’s UK operations, offering ongoing legal guidance as the company continues to grow and expand its services.

HOW CAN WE HELP YOU?

Looking to grow through strategic acquisitions? See how Dragon Argent’s integrated legal and financial expertise can support your M&A ambitions with precision and insight. Contact us today to find out how we can help your business achieve its next stage of growth.